Response to Osimertinib Observed in Meningeal-Metastatic NSCLC with EGFR A763V Mutation: A Case Report and Literature Review

Here, we report a case of a male patient who was initially diagnosed with stage IV driver gene-negative lung adenocarcinoma and received immune checkpoint inhibitors plus chemotherapy as first-line therapy. The patient progressed to meningeal metastasis and harbored an EGFR exon20 p.A763V mutation. A double dose of Osimertinib was recommended and the patient achieved a PFS of 10 months. This report offers evidence that Osimertinib may serve as a treatment option for patients with EGFR exon20 p.A763V mutation. In addition, dynamic spatiotemporal heterogeneity of lung cancer cells should be considered when treating patients with EGFR-positive NSCLC.